{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Larimar Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"LRMR"},"Address":{"label":"Address","value":"THREE BALA PLAZA EAST,SUITE 506, BALA CYNWYD, Pennsylvania, 19004, United States"},"Phone":{"label":"Phone","value":"+1 844 511-9056"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia."},"CompanyUrl":{"label":"Company Url","value":"https://www.larimartx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Carole S. Ben-Maimon","title":"President, Chief Executive Officer & Director"},{"name":"Noreen Scherer","title":"Vice President-Clinical Operations"},{"name":"Russell G. Clayton","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}